Latest News
Tuesday October 7, 2008 — StockWeb
Global stock markets are still in the selling pressure and volatility index VIX is already second week above 40 points. In fact this week index is oscillating around level of 50. This is right time for value investor for bargain searching. Many worthy stocks are below P/E 10 with still perspective...
Tuesday September 30, 2008 — Hagens Berman Sobol Shapiro
BOSTON, Sept. 29 /PRNewswire/ -- Two major pharmaceutical companies are facing the fire this week after U.S. District Judge Patti Saris approved two national classes in the Average Wholesale Price litigation, allowing plaintiffs to pursue litigation against AstraZeneca and Bristol-Myers Squibb C...
Monday September 29, 2008 — MedImmune
GAITHERSBURG, Md., Sept. 29 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to BIKEN, The Research Foundation for Microbial Diseases of Osaka University in Japan to support the development and construction of new vaccine strain...
Wednesday September 24, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 23 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES(R) (budesonide inhalation suspension) patent litigation.The court a...
Wednesday September 24, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 23 /PRNewswire-FirstCall/ -- AstraZeneca , a global leader in the pharmaceutical industry, has been named one of the "100 Best Companies" to work for by Working Mother magazine for the seventh consecutive year. This honor recognizes the company's commitment to family-frien...
Tuesday September 23, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April...
Tuesday September 16, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 15 /PRNewswire-FirstCall/ -- -- Results inconclusive, as primary outcome measure not statistically
significant for either donepezil or AZD3480; results impacted by
improvement in placebo group
-- Improvements shown on secondary outcome measures ADCS-CGIC and...
Friday September 12, 2008 — MedImmune
GAITHERSBURG, Md. and TOKYO, Sept. 11 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's a...
Wednesday September 10, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 10 /PRNewswire/ -- Recent survey findings indicate that most self-described US Hispanics lack an understanding of atherosclerosis despite their overall knowledge of cholesterol risk factors, treatment options and behavioral choices necessary to maintain a heart healthy lif...
Wednesday September 10, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ -- Newly released results from two previously published studies demonstrated patients receiving the maintenance combination asthma therapy SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol achieved bronchodilation, or open...
Thursday August 21, 2008 — MedImmune
GAITHERSBURG, Md., Aug. 21 /PRNewswire/ -- A new survey of parents of eight-to-17-year olds shows that vaccination ranks next to last among things they believe they can do to help protect against the influenza virus. Although public health guidelines state that getting an annual flu vaccination i...
Friday August 15, 2008 — AstraZeneca
SINGAPORE, Aug. 15 /PRNewswire-FirstCall/ -- AstraZeneca today announced an innovative new partnership with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds. The collaboration, which is spelt out in a Memorandum of Understan...
Thursday August 14, 2008 — Abbott
ABBOTT PARK, Ill. and WILMINGTON, Del., Aug. 14 /PRNewswire-FirstCall/ -- Abbott and AstraZeneca announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR(R) (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.Under the...
Tuesday August 12, 2008 — MedImmune
GAITHERSBURG, Md., Aug. 12 /PRNewswire/ -- MedImmune today announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus). The study is designed to asses...
Monday August 4, 2008 — MedImmune
GAITHERSBURG, Md., Aug. 4 /PRNewswire/ -- MedImmune announced today that it began shipping FluMist(R) (Influenza Virus Vaccine Live, Intranasal) on July 31 for the 2008-2009 influenza season. Early and wide availability of FluMist is a key component in maximizing opportunities to vaccinate an add...
Saturday August 2, 2008 — Zacks.com: Analyst Blog
AstraZeneca PLC's (AZN) key drugs such as Crestor (cholesterol), Seroquel (schizophrenia) and Symbicort (asthma) will continue to be the driving force of growth until the company can commercialize its pipeline. Company-wide revenue growth will slow considerably over the next few years due...
Friday August 1, 2008 — SchaeffersResearch
Sticking with my pharmaceutical theme, AstraZeneca
(AZN:
sentiment,
chart,
options)
announced that its profits increased to $1.11 per share, up from 95 cents per share a year earlier. Expectations called for a profit of $1.49 billion, which the company topped with its results of $...
Wednesday July 23, 2008 — AstraZeneca
WILMINGTON, Del., July 23 /PRNewswire-FirstCall/ -- More than a third of the people who contacted AstraZeneca to inquire about the company's prescription savings programs learned of the programs from their doctors or pharmacists, according to a year-long survey of more than 12,000 patients.The s...
Thursday July 10, 2008 — AstraZeneca
WILMINGTON, Del., July 10 /PRNewswire-FirstCall/ -- AstraZeneca announced today that it fully supports PhRMA's revised code guiding the pharmaceutical industry's interactions with healthcare providers, including new guidelines on promotional items, meals and sponsorship of meetings.The company i...
Wednesday July 2, 2008 — AstraZeneca
WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alle...
Tuesday June 24, 2008 — Zacks.com: Analyst Blog
AstraZeneca Plc's (AZN) key drugs such as Crestor (cholesterol), Seroquel (schizophrenia) and Symbicort (asthma) will continue to be the driving force of growth until the company can monetize its pipeline. Generic competition will eat into revenue growth, but productivity initiatives shou...
Thursday June 12, 2008 — Micromet, Inc.
BETHESDA and GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune announced today that the first patient has started treatment in a multi-center, phase 2 trial conducted in Germany investigating BiTE(R) antibody blinatumomab (MT103/MEDI-538) in patients with adult ac...
Saturday June 7, 2008 — MedImmune
GAITHERSBURG, Md., June 6 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, announced today that the Montgomery County Chamber of Commerce has presented Brian Rosen, senior director, government affairs, with its 2008 Chairman's Award at the organization's 49th Annual Dinner hel...
Wednesday June 4, 2008 — AstraZeneca
WILMINGTON, Del., June 4 /PRNewswire-FirstCall/ -- AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aeros...
Friday May 30, 2008 — AstraZeneca
WILMINGTON, Del., May 30 /PRNewswire-FirstCall/ -- AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) I.V. (esomeprazole sodium) for Injection to seek approval for use in patients with peptic ulcer...